Avalo Therapeutics rises as dosing begins in rare disease trial

Avalo Therapeutics

02/08/2022 13:55

** Avalo Therapeutics' shares  AVTX.O  rise 12.4% to $4.05
premarket
    ** Co doses first patient in late-stage study testing
AVTX-803 in Leukocyte Adhesion Deficiency Type II  urn:newsml:reuters.com:*:nGNX7LYGVn
    ** LAD II is a rare autosomal recessive disorder
characterized by immunodeficiency resulting in recurrent
infections
    ** 3 of 4 brokerages rate the stock "buy" or higher, 1
"hold"; their median PT is $40.50
    ** Stock down ~82.35% YTD as of last close

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com;))